By Catherine Eckford (European Pharmaceutical Review)2024-05-22T20:32:10
The approval means Sandoz’s Wyost® and Jubbonti® are the first biosimilars of denosumab authorised in Europe.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-30T10:47:00Z
Sponsored by CPhI
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-30T10:37:00
Sponsored by Shimadzu
2025-12-11T13:32:00
Sponsored by Hexagon
2025-09-17T08:00:00
Sponsored by Mastercontrol
2025-11-05T15:00:00
Sponsored by FUJIFILM Wako Pure Chemical Corporation
2026-04-29T14:00:00 2026-04-29T15:00:00
Sponsored by USP
Site powered by Webvision Cloud